NVCN - ネオバスク (Neovasc Inc.)

NVCNのニュース

   Neovasc : Management'sDiscussion and Analysis | MarketScreener  2020/08/06 21:14:04 MarketScreener
Neovasc Inc. Management's Discussion and Analysis FOR THE THREE AND SIX MONTHS ENDED JUNE 30,… | August 6, 2020
   Neovasc Announces Second Quarter Financial Results  2020/08/06 20:05:00 NewMediaWire
VANCOUVER and MINNEAPOLIS - (NewMediaWire) - August 06, 2020 - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, today reported financial results for the second quarter ended June 30, 2020. Second Quarter Highlights Following a COVID-related slowdown, experienced a sharp rebound in Reducer implants in June, meeting pre-COVID monthly Reducer target Confirmed FDA Circulatory Systems Devices Panel Meeting Date of Oct 27, 2020 Advanced CE Mark approval application for transapical Tiara TA mitral valve under Medical Device Directive Conducted further successful animal implants of transfemoral Tiara TF mitral valve replacement system “Cardiovascular diseases did not take a break during the quarter, and neither did Neovasc. We continue to pursue the promise of our novel devices to help patients with limited options for treating debilitating angina, and advancing at the forefront of mitral valve replacement technology,” said Fred Colen, Chief Executive Officer. “We continued to focus on the commercialization of the Reducer in the EU, and were pleased to see a sharp rebound of Reducer implants in June following the postponement of many elective surgical procedures.
   Neovasc : Announces Second Quarter Financial Results | MarketScreener  2020/08/06 18:49:02 MarketScreener
News Release August 6, 2020 Neovasc Announces Second Quarter Financial Results … | August 6, 2020
   Neovasc : Announces Closing of $11.5 MillionRegistered Direct Offering Priced At-The-Market | MarketScreener  2020/06/17 00:13:04 MarketScreener
News Release June 16, 2020 Neovasc Announces Closing of $11.5 Million … | June 17, 2020
   Neovasc : 5 NVC Q1 F20 MDA 200506 FINAL | MarketScreener  2020/05/21 20:48:06 MarketScreener
Neovasc Inc. Management's Discussion and Analysis FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND… | May 21, 2020
   Neovasc : Announces Closing of $11.5 MillionRegistered Direct Offering Priced At-The-Market | MarketScreener  2020/06/17 00:13:04 MarketScreener
News Release June 16, 2020 Neovasc Announces Closing of $11.5 Million … | June 17, 2020
   Neovasc : 5 NVC Q1 F20 MDA 200506 FINAL | MarketScreener  2020/05/21 20:48:06 MarketScreener
Neovasc Inc. Management's Discussion and Analysis FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND… | May 21, 2020
   Neovasc : 4 NVC Q1 F20 FS 200506 FINAL | MarketScreener  2020/05/21 20:48:06 MarketScreener
Neovasc Inc. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019 … | May 21, 2020
   Neovasc (NVCN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release  2020/04/30 16:34:01 Zacks Investment Research
Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO  2020/04/03 11:36:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2) BELLUS Health Inc (NASDAQ: BLU ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 2) BIOLASE Inc (NASDAQ: BIOL ) BioNano Genomics Inc (NASDAQ: BNGO ) (priced $18 million common stock and warrant offering) Celcuity Inc (NASDAQ: CELC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mediwound Ltd (NASDAQ: MDWD ) Merus NV (NASDAQ: MRUS ) Myokardia Inc (NASDAQ: MYOK ) Neovasc Inc (NASDAQ: NVCN ) Opko Health Inc. (NASDAQ: OPK ) PDS Biotechnology Corp (NASDAQ: PDSB ) Phio Pharmaceuticals Corp (NASDAQ: PHIO ) Precipio Inc (NASDAQ: PRPO ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Chanticleer Holdings Common Stock (NASDAQ: SONN ) Vaccinex Inc (NASDAQ: VCNX ) Stocks In Focus Fate Announces CAR T-cell Therapy Licensing Deal With J&J's Janssen Unit Fate Therapeutics Inc (NASDAQ: FATE ) said it has entered into a global collaboration and option agreement with Johnson & Johnson (NYSE: JNJ )'s Janssen unit, under which it will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor, or CAR, NK and CAR T-cell product candidates.
   Neovasc : Announces Closing of $11.5 MillionRegistered Direct Offering Priced At-The-Market | MarketScreener  2020/06/17 00:13:04 MarketScreener
News Release June 16, 2020 Neovasc Announces Closing of $11.5 Million … | June 17, 2020
   Neovasc : 5 NVC Q1 F20 MDA 200506 FINAL | MarketScreener  2020/05/21 20:48:06 MarketScreener
Neovasc Inc. Management's Discussion and Analysis FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND… | May 21, 2020
   Neovasc : 4 NVC Q1 F20 FS 200506 FINAL | MarketScreener  2020/05/21 20:48:06 MarketScreener
Neovasc Inc. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE THREE MONTHS ENDED MARCH 31, 2020 AND 2019 … | May 21, 2020
   Neovasc (NVCN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release  2020/04/30 16:34:01 Zacks Investment Research
Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   The Daily Biotech Pulse: Fate Therapeutics Inks Cell Therapy Deal With J&J, Zentalis IPO  2020/04/03 11:36:23 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 2) BELLUS Health Inc (NASDAQ: BLU ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows April 2) BIOLASE Inc (NASDAQ: BIOL ) BioNano Genomics Inc (NASDAQ: BNGO ) (priced $18 million common stock and warrant offering) Celcuity Inc (NASDAQ: CELC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) ENDRA Life Sciences Inc (NASDAQ: NDRA ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Madrigal Pharmaceuticals Inc (NASDAQ: MDGL ) Mediwound Ltd (NASDAQ: MDWD ) Merus NV (NASDAQ: MRUS ) Myokardia Inc (NASDAQ: MYOK ) Neovasc Inc (NASDAQ: NVCN ) Opko Health Inc. (NASDAQ: OPK ) PDS Biotechnology Corp (NASDAQ: PDSB ) Phio Pharmaceuticals Corp (NASDAQ: PHIO ) Precipio Inc (NASDAQ: PRPO ) Seelos Therapeutics Inc (NASDAQ: SEEL ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Chanticleer Holdings Common Stock (NASDAQ: SONN ) Vaccinex Inc (NASDAQ: VCNX ) Stocks In Focus Fate Announces CAR T-cell Therapy Licensing Deal With J&J's Janssen Unit Fate Therapeutics Inc (NASDAQ: FATE ) said it has entered into a global collaboration and option agreement with Johnson & Johnson (NYSE: JNJ )'s Janssen unit, under which it will apply its iPSC product platform to research and preclinically develop new iPSC-derived chimeric antigen receptor, or CAR, NK and CAR T-cell product candidates.

calendar